Scholarlink

<p>Alzheimer’s disease (AD), a devastating neurodegenerative disorder characterized by synaptic loss, cognitive decline, oxidative stress, neurotransmitter imbalance, amyloid-β accumulation, tau tangles, chronic neuroinflammation, and dysregulated signaling, is further exacerbated by endothelin (ET) system dysregulation, where elevated ECE-2 and ET-1 correlate with Aβ-driven pathology in vitro and in vivo. Against this backdrop, Sovateltide (IRL-1620), a highly selective endothelin-B receptor agonist, has emerged as a next-generation, multi-target therapeutic with remarkable neuroprotective promise. Preclinical studies reveal that Sovateltide promotes neurogenesis, synaptogenesis, and angiogenesis, preserves mitochondrial function, and enhances neuronal survival. At the molecular level, it fine-tunes pivotal AD-related pathways, including MAPK, NF-κB, PI3K/Akt/mTOR, Notch, Wnt/β-catenin, and NLRP3 inflammasome, thereby suppressing the release of pro-inflammatory cytokines, inhibiting BACE1 activity, and mitigating the amyloid-β burden. Functionally, Sovateltide enhances learning, memory, and synaptic plasticity in Aβ-induced rodent models, while reducing oxidative stress and increasing neurotrophic factors, including BDNF and NGF. Early clinical evidence highlights its favorable safety and tolerability, as well as its potential cognitive benefits, reinforcing its translational relevance. Beyond neuroprotection, this review underscores how Sovateltide aligns with the emerging heart–brain axis paradigm by targeting vascular dysfunction and modulating convergent signaling pathways, including MAPK, NF-κB, PI3K/Akt/mTOR, Notch, Wnt/β-catenin, and the NLRP3 inflammasome that orchestrate both cardiovascular and neurological decline. This dual action positions it not only as a potential disease-modifying therapy for AD but also as a therapeutic bridge to neurocardiac and psychocardiac disorders. Looking forward, multicenter clinical trials, biomarker-driven patient stratification, and combinatorial strategies will be crucial in validating its efficacy and integrating Sovateltide within the precision medicine framework for dementia care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sovateltide at the heart–brain axis crosstalk in Alzheimer’s disease: a promising multi-target and cutting-edge therapeutic approach

  • 期刊论文

  • 发表日期：

    2026年3月30日

查看全文
  • Shiv Kumar Kushawaha,
  • Kanika Vashisht,
  • Himanshu Kumar,
  • Amar Deep Anaklgi,
  • Mahendra Singh Ashawat,
  • Ashish Baldi

摘要

Alzheimer’s disease (AD), a devastating neurodegenerative disorder characterized by synaptic loss, cognitive decline, oxidative stress, neurotransmitter imbalance, amyloid-β accumulation, tau tangles, chronic neuroinflammation, and dysregulated signaling, is further exacerbated by endothelin (ET) system dysregulation, where elevated ECE-2 and ET-1 correlate with Aβ-driven pathology in vitro and in vivo. Against this backdrop, Sovateltide (IRL-1620), a highly selective endothelin-B receptor agonist, has emerged as a next-generation, multi-target therapeutic with remarkable neuroprotective promise. Preclinical studies reveal that Sovateltide promotes neurogenesis, synaptogenesis, and angiogenesis, preserves mitochondrial function, and enhances neuronal survival. At the molecular level, it fine-tunes pivotal AD-related pathways, including MAPK, NF-κB, PI3K/Akt/mTOR, Notch, Wnt/β-catenin, and NLRP3 inflammasome, thereby suppressing the release of pro-inflammatory cytokines, inhibiting BACE1 activity, and mitigating the amyloid-β burden. Functionally, Sovateltide enhances learning, memory, and synaptic plasticity in Aβ-induced rodent models, while reducing oxidative stress and increasing neurotrophic factors, including BDNF and NGF. Early clinical evidence highlights its favorable safety and tolerability, as well as its potential cognitive benefits, reinforcing its translational relevance. Beyond neuroprotection, this review underscores how Sovateltide aligns with the emerging heart–brain axis paradigm by targeting vascular dysfunction and modulating convergent signaling pathways, including MAPK, NF-κB, PI3K/Akt/mTOR, Notch, Wnt/β-catenin, and the NLRP3 inflammasome that orchestrate both cardiovascular and neurological decline. This dual action positions it not only as a potential disease-modifying therapy for AD but also as a therapeutic bridge to neurocardiac and psychocardiac disorders. Looking forward, multicenter clinical trials, biomarker-driven patient stratification, and combinatorial strategies will be crucial in validating its efficacy and integrating Sovateltide within the precision medicine framework for dementia care.